Teva-Emtricitabine/Tenofovir · DIN 02399059 · 200 mg & 300 mg · tablet
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Emtricitabine/Tenofovir · DIN 02399059
Manufacturer: Teva Canada Limited; listing date 2017-09-28
Health Canada: Marketed since 2017-07-26 · brand TEVA-EMTRICITABINE/TENOFOVIR · ATC J05AR03 TENOFOVIR DISOPROXIL AND EMTRICITABINE · form Tablet · route Oral · ingredients EMTRICITABINE 200 MG, TENOFOVIR DISOPROXIL FUMARATE 300 MG · company Teva canada limited · schedule Prescription
Teva-Emtricitabine/Tenofovir: Formulary list price $7.30 per unit (the source does not state the unit; exact figure $7.3035). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02399059)
Source record
DIN 02399059: Teva-Emtricitabine/Tenofovir
Raw flags: sec3=Y
Item: 081800099; group id 84; item number 0152; lccId None; manufacturer id TEV
Source form: Tab; strength: 200mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $7.3035; ministry $7.3035
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02399059
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88396
Interchangeable products
AG-Emtricitabine & Tenofovir Disoproxil · DIN 02496356 · $7.3035
Apo-Emtricitabine-Tenofovir · DIN 02452006 · $7.3035
Auro-Emtricitabine-Tenofovir · DIN 02490684 · $7.3035
Jamp-Emtricitabine/Tenofovir Disoproxil · DIN 02487012 · $7.3035
Mint-Emtricitabine/Tenofovir · DIN 02521547 · $7.3035
Mylan-Emtricitabine/Tenofovir Disoproxil · DIN 02443902 · $7.3035
PMS-Emtricitabine/Tenofovir · DIN 02461110 · $7.3035
Truvada · DIN 02274906 · $7.3035
Shortage status: not checked (no credentials)